{
    "clinical_study": {
        "@rank": "149682", 
        "arm_group": [
            {
                "arm_group_label": "HBeAg positive group", 
                "arm_group_type": "Other", 
                "description": "Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .\nBlank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
            }, 
            {
                "arm_group_label": "HBeAg-negative group", 
                "arm_group_type": "Other", 
                "description": "Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .\nBlank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of Entecavir maleate\n      tablets in Chinese patients with hepatitis B"
        }, 
        "brief_title": "Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects diagnosed of HBeAg  positive or negative chronic hepatitis B\n\n          2. Aged 18 to 70 years old\uff0cmale or female\n\n          3. Patients  with previously HBsAg-positive, HBeAg-positive for 24 weeks, HBV-DNA>\n             105copies/ml. HBeAg-negative for 24 weeks or more, HBV-DNA> 105 copies/ml.\n\n          4. 1.3 times the upper normal limit (1.3 \u00d7 ULN) \u2264 alanine aminotransferase (ALT) \u2264 10 \u00d7\n             ULN.\n\n          5. Total serum bilirubin (TBIL) \u2264 2.5 \u00d7 ULN.\n\n          6. Prothrombin activity (PTA) \u2265 60% or prothrombin time prolonged than normal \u2264    3\n             seconds).\n\n          7. WBC \u2265 3.5 \u00d7 109 / L, PLT \u2265 70 \u00d7 109 / L, serum albumin (ALB)\u2265 35 g / L.\n\n          8. Creatinine (Cr) \u2264 1.5 \u00d7 ULN.\n\n          9. If patients take intermittently with interferon, nucleoside (acid) analogues, \u03b11\n             thymosin before enrollment with 24 weeks, the time is  no more than 12 weeks.\n\n         10. Patients signed an informed consent form and compliance was good.\n\n        Exclusion Criteria:\n\n          1. Patients were infected with other viruses as HAV, HCV, HDV, HEV, CMV, EBV, HIV etc.\n\n          2. Patients with cirrhosis or liver cancer.\n\n          3. Patients have participated in another therapeutic clinical trial in 3 months.\n\n          4. Granulocyte count <1.5 \u00d7 109 / L, hemoglobin (HB)<100g / L, sera\n             alpha-fetoprotein(AFP)> 100\u03bcg / L, patients' B ultrasonography  pointed\n             space-occupying lesions.\n\n          5. Patients with severe heart, kidney, endocrine hematopoietic system and\n             neuropsychiatric diseases.\n\n          6. Patients with metabolic or autoimmune diseases such as systemic lupus erythematosus.\n\n          7. Pregnant woman, lactating women or those who wre allergic for study drug."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "287", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926288", 
            "org_study_id": "CTTQ805-4"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "HBeAg positive group", 
                    "HBeAg-negative group"
                ], 
                "intervention_name": "Entecavir maleate tablets", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "HBeAg positive group", 
                    "HBeAg-negative group"
                ], 
                "intervention_name": "blank Baraclude tablets", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "HBeAg positive group", 
                    "HBeAg-negative group"
                ], 
                "intervention_name": "Blank maleate entecavir tablets", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "HBeAg positive group", 
                    "HBeAg-negative group"
                ], 
                "intervention_name": "Baraclude tablets", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Maleic acid", 
                "Entecavir"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100034"
                    }, 
                    "name": "Department of Infectious Diseases,Peking University First Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100054"
                    }, 
                    "name": "Beijing You An Hospital,Capital Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Chongqing", 
                        "zip": "400038"
                    }, 
                    "name": "The First Affiliated Hospital Of The Third Mililary Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei", 
                        "zip": "430030"
                    }, 
                    "name": "Tongji Medical College of Hust Tongji Medical College Huazhong University of Science and Technology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210029"
                    }, 
                    "name": "The First Affiliated Hospital Of Nanjing Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai", 
                        "zip": "200025"
                    }, 
                    "name": "Shanghai Jiaotong University Affiliated Ruijin Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "400010"
                    }, 
                    "name": "West China Hospital Of Sichuan University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "400010"
                    }, 
                    "name": "The Second Affiliated Hospital Of Chongqing Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310003"
                    }, 
                    "name": "The First Affiliated Hospital Of Zhejiang University"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B", 
        "overall_official": [
            {
                "affiliation": "Department of Infectious Diseases,Peking University First Hospital", 
                "last_name": "Yu Yan yan, doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Huashan Hospital, Fudan University", 
                "last_name": "Shi Guang feng, doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Shanghai Jiaotong University Affiliated Ruijin Hospital", 
                "last_name": "Xie Qing, doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "West China Hospital", 
                "last_name": "Tang Hong, doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Second Affiliated Hospital of Chongqing Medical University", 
                "last_name": "Zhang Da zhi, doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The First Affiliated Hospital Of The Third Mililary Medical University", 
                "last_name": "Mao Qing, doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Tongji Medical College of Hust Tongji Medical College Huazhong University of Science and Technology", 
                "last_name": "Ning Qin, doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The First Affiliated Hospital Of Nanjing Medical University", 
                "last_name": "Li Jun, doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Zhejiang University", 
                "last_name": "Sheng Ji fang, doctor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Beijing You An Hospital,Capital Medical University", 
                "last_name": "Cheng Xin fang, doctor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Compared with baseline, decline of serum HBV-DNA  in the value", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926288"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}